Related Experiment Video
Updated: May 4, 2026
18:48
In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
Published on: August 12, 2017
13.8K
Prospects for therapeutic tolerance in humans.
Kenneth F Baker1, John D Isaacs
1The National Institute for Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, UK.
Current Opinion in Rheumatology
|January 1, 2014
Summary
Recent advances in therapeutic tolerance show promise for treating autoimmune diseases and improving transplant outcomes. Early detection and new biomarkers are key to advancing these innovative tolerogenic therapies.
Area of Science:
- Immunology
- Transplantation Medicine
- Autoimmunity
Background:
- Therapeutic tolerance research has historically faced slow progress.
- Recent breakthroughs bridge the gap between animal models and clinical applications.
- Understanding immune tolerance is crucial for managing autoimmune conditions and transplant rejection.
Purpose of the Study:
- To review recent advancements in therapeutic tolerance.
- To explore future possibilities for inducing immune tolerance.
- To highlight emerging strategies for autoimmune disease and transplantation.
Main Methods:
- Review of current clinical trials and preclinical research.
- Analysis of novel therapeutic approaches including cell therapy and monoclonal antibodies.
- Investigation of the role of hematopoietic chimerism and the microbiome in immune tolerance.
Main Results:
- Successful allograft survival with immunosuppressant withdrawal in select transplant recipients.
- Promising results from mesenchymal stromal cell therapy in autoimmune diseases.
- Demonstrated efficacy of regulatory T cells and targeted monoclonal antibodies in clinical trials for various immune-mediated conditions.
- Emerging evidence on the microbiome's role in immune tolerance.
Conclusions:
- Recent research has significantly advanced the clinical application of therapeutic tolerance.
- Early detection of autoimmunity presents opportunities for intervention.
- Development of reliable biomarkers for tolerance is essential for effective treatment monitoring and immunosuppressant withdrawal.
More Related Videos
Related Concept Videos
01:23Toxicity Testing in Animals
204
Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
204
01:25Analgesia and Pain Management
3.3K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
3.3K
01:20Desensitization and Tachyphylaxis
3.4K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
3.4K
01:20Special Features of Adaptive Immunity
3.7K
The adaptive immune system, a crucial component of the overall immune response, offers a highly specialized defense against pathogens. It involves specific cell types and features, enabling it to combat infections effectively and efficiently.
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
3.7K
01:28Preclinical Development: Overview
4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81